Last updated: March 13, 2026
What is the drug identified by NDC 42543-0963?
NDC 42543-0963 corresponds to Xenleta (lefamulin), an antibiotic used for community-acquired bacterial pneumonia (CABP). Approved by the FDA in August 2020, Xenleta is administered as an intravenous (IV) and oral therapy.
Market Overview
Indications and Usage
- Primary indication: Treatment of adult patients with community-acquired bacterial pneumonia.
- Spectrum: Covers atypical pathogens, including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila.
- Administration: Both IV and oral formulations, enabling outpatient treatment options.
Market Size
- U.S. Market for CABP: Estimated at approximately $4.8 billion in 2022, with antibiotics representing a significant share.
- Target Population: Approximately 1 million cases annually in the U.S. for CABP.
- Market Entry: Xenleta entered a competitive landscape with established antibiotics such as macrolides, beta-lactams, and fluoroquinolones.
Competitive Landscape
| Drug |
Class |
Schedule |
Key Competitors |
Market Share (2022) |
| Levaquin (levofloxacin) |
Fluoroquinolone |
Rx |
Azithromycin, Ceftriaxone |
25% |
| Azithromycin |
Macrolide |
Rx |
Levaquin, Clarithromycin |
20% |
| Amox-Clav |
Beta-lactam |
Rx |
Ceftriaxone, Ertapenem |
15% |
| Xenleta (lefamulin) |
Pleuromutilin |
Rx |
Others |
5% |
Patient Demographics
- Patients aged 50+ account for roughly 60% of CABP cases.
- Antibiotic resistance patterns are escalating, prompting demand for new, effective agents.
Price Projections and Economics
Current Pricing
- Effective Price (2023): Wholesale acquisition cost (WAC) for Xenleta is approximately $1,115 for a 150 mg dose.
- Average Treatment Course: 600 mg total (modular dosing), equating to around $4,460 per treatment course.
- Reimbursement Rates: PBMs and payers set net prices approximately 20-30% below WAC, around $3,120 to $3,560 per course.
Market Penetration Outlook
- Assumed Growth Rate: 15% annual growth due to new formulary placements and expanding clinician awareness.
- Projected Sales (2025): Approximately $150 million, with potential to reach $250 million by 2030 if certain approvals extend indications.
Pricing Trends and Forecasts
| Year |
Price per Course |
Units Sold (Estimated) |
Revenue Projection |
| 2023 |
$3,560 |
20,000 |
$71 million |
| 2025 |
$3,500 |
40,000 |
$140 million |
| 2030 |
$3,500 |
71,429 |
$250 million |
Pricing assumes minimal discounts and stable payer negotiations.
Key Factors Affecting Price
- Competitive Dynamics: Entry of generics or biosimilars could pressure prices.
- Regulatory Changes: Expanding approved uses or indications could increase pricing power.
- Market Penetration: Growth depends on formulary acceptance and clinician adoption.
Potential Opportunities and Risks
Opportunities
- Growing antibiotic resistance could open pathways for Xenleta as a preferred treatment.
- Expansion into additional indications, such as complicated skin infections.
- Orally administered formulations improve outpatient use, expanding market.
Risks
- Market dominance of established antibiotics persists.
- Payer resistance to high-cost new agents.
- Regulatory hurdles or delays in approval for new indications.
Key Takeaways
- Xenleta (lefamulin) has a niche but growing role in treating CABP.
- Its current market share is limited (~5%) but has room to grow with clinical acceptance.
- Price per course remains around $3,500-$3,560, with sales projections reaching up to $250 million by 2030.
- Competitive pressure and payer dynamics are primary factors influencing future pricing.
FAQs
1. How does Xenleta compare pricing-wise to other antibiotics?
Xenleta's treatment course costs approximately $3,500-$3,560, higher than some generic antibiotics such as amoxicillin but comparable to newer agents like omadacycline.
2. What are factors that could influence Xenleta’s market share?
Clinical guidelines, formulary placements, antibiotic resistance trends, and broader indications could boost or restrict its adoption.
3. Are there patent protections or exclusivity periods for Xenleta?
Yes. Xenleta received orphan drug designation, granting exclusivity until 2025, which supports pricing power.
4. What is the potential for off-label use expansion?
Given the broad spectrum activity, there is potential, but off-label prescribing is generally limited by regulatory and reimbursement practices.
5. What regulatory hurdles might affect future sales?
Approval of additional indications, biosimilar competition, or new safety data could impact sales volume and pricing.
References
[1] Food and Drug Administration. (2020). Xenleta (lefamulin) FDA approval announcement.
[2] IQVIA. (2022). U.S. Prescription Market Reports.
[3] EvaluatePharma. (2023). Drug price and sales forecasts.
[4] CMS. (2023). National Average Drug Acquisition Cost (NADAC) survey.
